Mark Pimentel.

For the TARGET Study Group: Rifaximin Therapy for Sufferers with Irritable Bowel Syndrome without Constipation The irritable bowel syndrome is a functional gastrointestinal disorder characterized by recurring symptoms of abdominal pain, bloating, and altered bowel function in the lack of structural, inflammatory, or biochemical abnormalities.1 IBS often will not respond to current treatment options, including dietary and way of life modifications, fiber supplementation, psychological therapy, and pharmacotherapy.2,3 Because zero reliable biologic or structural markers have been identified, the effects of pharmacotherapy are typically assessed by asking patients to report whether they had adequate comfort of IBS symptoms .4 Given the restrictions of available therapies, there is an unmet medical need for novel therapeutic approaches.These results raise important new questions about the best technique for reducing the chance of this important complication, which affects about one in five sufferers undergoing colorectal surgery still, despite skin administration and decontamination of systemic antibiotics.3-7 Our data don’t allow us to identify with certainty the cause of the lack of efficacy we observed. Nevertheless, we can speculate that several factors may have been operational. First, though the microorganisms cultured from contaminated surgical wounds were comparable in distribution between the two study groups , cultures from the sponge group contained a lot more resistant bacterias than cultures from the control group.